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Background-—Mitochondrial dysfunction has been shown to play an important role in the development of atherosclerosis and
nonalcoholic fatty liver disease (NAFLD). Mitochondrial aldehyde dehydrogenase (ALDH2), an enzyme responsible for the
detoxification of reactive aldehydes, is considered to exert protective function in mitochondria. We investigated the influence of
Alda-1, an activator of ALDH2, on atherogenesis and on the liver steatosis in apolipoprotein E knockout (apoE/) mice.
Methods and Results-—Alda-1 caused decrease of atherosclerotic lesions approximately 25% as estimated by “en face” and
“cross-section” methods without influence on plasma lipid profile, atherosclerosis-related markers of inflammation, and
macrophage and smooth muscle content in the plaques. Plaque nitrotyrosine was not changed upon Alda-1 treatment, and there
were no changes in aortic mRNA levels of factors involved in antioxidative defense, regulation of apoptosis, mitogenesis, and
autophagy. Hematoxylin/eosin staining showed decrease of steatotic changes in liver of Alda-1-treated apoE/ mice. Alda-1
attenuated formation of 4-hydroxy-2-nonenal (4-HNE) protein adducts and decreased triglyceride content in liver tissue. Two-
dimensional electrophoresis coupled with mass spectrometry identified 20 differentially expressed mitochondrial proteins upon
Alda-1 treatment in liver of apoE/ mice, mostly proteins related to metabolism and oxidative stress. The most up-regulated were
the proteins that participated in beta oxidation of fatty acids.
Conclusions-—Collectively, Alda-1 inhibited atherosclerosis and attenuated NAFLD in apoE/ mice. The pattern of changes
suggests a beneficial effect of Alda-1 in NAFLD; however, the exact liver functional consequences of the revealed alterations as
well as the mechanism(s) of antiatherosclerotic Alda-1 action require further investigation. ( J Am Heart Assoc. 2014;3:e001329
doi: 10.1161/JAHA.114.001329)
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A therosclerosis and its complications are the leadingcauses of mortality in Western countries.1 Atheroscle-
rosis is a chronic inflammatory disease of the arterial wall,
characterized by endothelial dysfunction, infiltration of inflam-
matory cells, and finally, formation of atherosclerotic plaque
with its lipid-rich core and rupture-prone fibrous cap.2 A
growing body of evidence shows that nonalcoholic fatty liver
disease (NAFLD), the most common liver disorder, is an
important independent risk factor for development of athero-
sclerosis.3 NAFLD is primarily manifested by various extents
of triglyceride (TG) accumulation in hepatocytes, but encom-
passes a broad spectrum of pathological conditions ranging
from simple steatosis (accumulation of fat) to steatohepatitis
(steatosis accompanied by inflammatory response), fibrosis,
and, finally, hepatocellular carcinoma.4
Recently, it has been proposed that mitochondrial dysfunc-
tion could represent a common mechanistic background for
the development of atherosclerosis and NAFLD.5–7 Many
factors related to endothelial injury and atherogenesis (eg,
proinflammatory cytokines and hypercholesterolemia) have
been shown to increase mitochondrial reactive oxygen species
(ROS) generation and impair major mitochondrial functions,
leading to decreased cellular production of ATP, derangement
of lipid, steroid, and aminoacid metabolism, as well as
dysregulation of cell cycle and increase of apoptosis.8,9
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Excessive production of ROS by dysfunctional mitochondria
leads to oxidative modification of mitochondrial proteins,
lipids, and DNA and subsequent further impairment of
mitochondria. ROS-dependent peroxidation of polyunsaturated
fatty acids is associated with generation of toxic aldehydes,
such as 4-hydroxy-2-nonenal (4-HNE) and acrolein,10 which are
highly reactive toward thiols and amino groups of cysteine,
histidine, and lysine; hence, 4-HNE can easily form adducts
with proteins and affect their function. Importantly, accumu-
lation of 4-HNE has been described in atherosclerosis, NAFLD,
diabetes, ischemia, and neurodegenerative diseases.11,12
Mitochondrial aldehyde dehydrogenase (ALDH2), mostly
known for its role in ethanol metabolism, is a key enzyme
involved in the degradation of toxic reactive aldehydes, such
as 4-HNE and acrolein, to unreactive acids and therefore play
a role in mitochondrial protection. Activation of ALDH2 has
been proposed as a potential therapeutic strategy in cardio-
vascular diseases (CVDs).13 Recently, a small-molecular-
weight activator of ALDH2—N-(1,3-benzodioxol-5-ylmethyl)-
2,6-dichlorobenzamide (Alda-1)—has been described.14,15
Interestingly, ALDH2 activation by Alda-1 has been shown
to restore angiogenesis and prevent b-amyloid-induced
endothelial dysfunction in vitro and exert protective action
against acute ischemic injury in the heart.15,16 However, there
is no information whether prolonged activation of ALDH2 may
offer any benefits in chronic processes associated with
mitochondrial accumulation of aldehydes. Thus, we hypothe-
sized that by increasing the detoxification activity of ALDH2
by use of the selective ALDH2 activator, Alda-1, we would be
able to reduce atherosclerosis and NAFLD.
Apolipoprotein E (apoE)-knockout mice (apoE/) are
widely used in atherosclerosis studies because they sponta-
neously develop hypercholesterolemia, dyslipidemia, and
arterial lesions.17 Importantly, apoE/mice along with ath-
erosclerosis develop, over 6 months, changes in liver resem-
bling mild hepatic steatosis and fibrosis.18 The aim of our study
was to comprehensively examine the influence of prolonged
treatment with Alda-1 on the development of atherosclerotic
plaques and fatty liver in apoE/ mice using morphological,
biochemical, molecular, and proteomic methods.
Methods
Animal Experiments
All animal procedures were performed to conform to the
guidelines from Directive 2010/63/EU of the European Parlia-
ment on the protection of animals used for scientific purposes
and approved by the Jagiellonian University Ethical Committee
on Animal Experiments (no. 73/2011). Female apoE-knockout
mice, on a C57BL/6J background, were obtained from Taconic
(Ejby, Denmark). Mice were maintained on 12-hour dark/light
cycles in air-conditioned rooms (22.50.5°C, 505% humidity)
with access to diet and water ad libitum in the Animal House of
Chair of Immunology of Jagiellonian University Medical College
(Krakow, Poland). At the age of 8 weeks,micewere put on chow
diet made by Ssniff (Soest, Germany). Two groups of animals
were studied: control group (apoE/ mice wthout treatment,
on chowdiet as above; n=10) andAlda-1-treatedmice (n=10). In
this group, Alda-1 (ChemBridge, San Diego, CA) was mixed
without heating with the same diet and administered to mice at
a dose of 10 mg per kg of body weight per day (according to a
calculation taking into account average body mass of mice and
their daily diet requirement). At the age of 6 months, mice from
both groups were killed using a carbon monoxide chamber
5 minutes after injection of fraxiparine (1000 UI; Sanofi-
Synthelabo, Paris, France) into the peritoneum. Next, the blood
from the right ventricle was collected and hearts, livers, and
aortas were dissected.
Quantification of Atherosclerosis: “En Face”
Method
The aorta from arch to bifurcation was fixed in 4% formalde-
hyde. Then, it was opened longitudinally, pinned onto black
wax plates, and stained with Sudan-IV (Sigma-Aldrich, St.
Louis, MO). Aortic lesion and total aortic areas were
calculated using LSM Image Browser software.
Quantification of Atherosclerosis:
“Cross-Section” Method
The heart and ascending aorta were embedded in optimal
cutting temperature compound (CellPath, Newtown, UK) and
snap-frozen. Ten-micrometer-thick cryosections were cut
from the proximal 1 mm of the aortic root. Eight adjacent
sections were collected at 100-lm intervals starting at a 100-
lm distance from the appearance of the aortic valves.
Sections were thaw-mounted on poly-L-lysine–coated slides
and air dried. After fixation in 4% paraformaldehyde (pH 7.0),
sections were stained with Oil Red O (ORO; Sigma-Aldrich).
ORO-stained sections were examined under an Olympus BX50
(Olympus, Tokyo, Japan) microscope and used for quantitative
evaluation. Images of the aorta were recorded using an
Olympus Camedia DP71 digital camera. Total area of the
lesion was measured semiautomatically in each slide using
LSM Image Browser software (Zeiss, Jena, Germany). For each
animal, a mean lesion area was calculated from 8 sections,
reflecting the cross-section area covered by atherosclerosis.
Immunohistochemistry Staining of Aortic Roots
For indirect immunohistochemistry (IHC), acetone-fixed
sections of ascending aorta were used. Sections were
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preincubated overnight with 5% of nonimmunogenic goat
serum with 2% fat-free milk to block nonspecific binding of
antibodies (Abs). Incubations with primary Abs were per-
formed overnight at room temperature in wet chambers in
the following combination of sera: cyanine 3 (Cy3)-conju-
gated anti-alpha-smooth muscle actin (a-SMA; dilution 1:800;
Sigma-Aldrich) and rat anti-mouse CD68 (dilution 1:800;
Serotec, Kidlington, UK). Then, goat anti-rat immunoglobulin
G biotinylated Abs, followed by dichlorotriazinylaminofluores-
cein (DTAF)-conjugated streptavidin (Jackson ImmunoRe-
search, West Grove, PA), were applied to visualize rat Abs.
Sections were examined using an epifluorescence Olympus
BX50 microscope equipped with appropriate filter cubes to
show Cy3 (red) and DTAF (green) fluorescence. Images were
registered with a Camedia DP71 digital camera (Olympus). In
each section, the total area occupied by CD68-immunopos-
itive macrophages and a-SMA-positive cells were measured
using LSM Image Browser software. For staining of 4-HNE-
protein adducts and nitrotyrosine, a primary monoclonal
mouse antibody, anti-4-hydroxynonenal (HNEJ-2; Abcam,
Cambridge, MA), and a polyclonal rabbit antibody, anti-
nitrotyrosine (Sigma-Aldrich), were used. IHC was performed
using a standard protocol. Slides were dewaxed, rehydrated,
and incubated in a 3% peroxide solution to block endogenous
peroxidase activity. Antigen retrieval was carried out by
water bath cooking in citrate buffer (pH 6.0). The LabVision
(Thermo Fisher Scientific, Fremont, CA) detection system
was used, and 3,30-diaminobenzidine (DAB) served as the
chromogen. Slides were counterstained with Mayer’s hema-
toxylin. The intensity of the IHC reaction was evaluated using
a light microscope (Nikon eclipse 50i; Nikon, Tokyo, Japan).
Real-Time Reverse-Transcriptase Polymerase
Chain Reaction
Total RNA was isolated from the homogenized mouse aortas
using the RNeasy Fibrous Tissue Mini Kit (QIAGEN, Valencia,
CA), according to the manufacturer’s instructions. Extracted
RNA was dissolved in 30 lL of nuclease-free water (Fermen-
tas Canada, Burlington, Ontario, Canada). The RNA concen-
tration of each sample was measured at a wavelength of
260 nm (A260) in an EPOCH microplate spectrophotometer
(BioTek Instruments, Inc., Winooski, VT). The purity of
extracted total RNA was determined by the A260/A280
ratio. cDNA was synthesized by the reverse transcription of
1000 ng of total RNA from each sample using 0.5 lL of oligo
(dT)18 primer (Fermentas Canada) and 0.4 lL of M-MuLV
reverse transcriptase (200 U/lL; Fermentas Canada) in a
total volume of 10 lL (including also: 2 lL 59 reaction buffer
for M-MuLV RT [containing 250 mmol/L of Tris-HCl (pH 8.3)
at 25°C, 250 mmol/L of KCl, 20 mmol/L of MgCl2, and
50 mmol/L DTT], 0.5 lL of dNTPs mixture [10 mmol/L],
0.3 lL of RiboLock RNAse Inhibitor [40 U/lL], and nuclease-
free water; Fermentas). The reaction was performed in a T3
Thermocycler (Biometra, G€ottingen, Germany) at 42°C during
1 hour, and the enzyme was then denatured at 95°C for
5 minutes. The cDNA was diluted 8-fold before polymerase
chain reaction (PCR) amplification.
Relative gene expression analysis in aortas, with GAPDH as
the internal reference gene, was carried out using the 7900HT
fast real-time PCR System (Applied Biosystems, Foster City, CA)
in triplicate. Primers were designed with Primer BLAST software
(http://www.ncbi.nlm.nih.gov/tools/primer-blast) for Atg5,
Lc3a, Lc3b, Becn1, Ppargc1a, and Sirt1 genes or purchased
using commercially available TaqMan Gene Expression Assays
(Applied Biosystems) for Bax, Bcl2, Cat, Gpx1, and Sod2 genes.
Sequences of the designed primerswere as follows: 50 ACCACA
AGCAGC TCTGGA TGGGAC T 30 (forward) and 50 GCCGCTCCG
TCG TGG TCT GAT AT 30 (reverse) for Atg5; 50 TTG GTC AAG ATC
ATC CGG C 30 (forward) and 50 GCT CAC CAT GCT GTG CTG G 30
(reverse) for Lc3a; 50 CAC TGC TCT GTC TTG TGT AGG TTG 30
(forward) and 50 TCG TTG TGCCTT TAT TAG TGCATC30 (reverse)
for Lc3b; 50 GGGGTT TGCGGT TTT TCT GGG AC 30 (forward) and
50 TCT CCA CGT CCA TCC ATC CTG TAC GGA AG 30 (reverse) for
Becn1; 50 CCT TGGAGCAGGTTGCAGGAA TCC30 (forward) and
50 AGG GCA CCG AGG AAC TAC CTG ATT 30 (reverse) for Sirt1;
and 50 TCA CTC TCA GTA AGG GGC TGG TTG C 30 (forward) and
50 TCC TCA CCA ACC AGA GCA GCA CAC 30 (reverse) for
Ppargc1a. Reactions were carried out using GoTaq quantitative
PCR Master Mix (Promega, Madison, WI) or TaqMan Gene
Expression Master Mix (Applied Biosystems), according to the
manufacturer’s instructions. Analysis of the data was per-
formed using Data Assist v3.01 software (Applied Biosystems).
Histology and IHC of the Liver
Samples of liver tissue were formalin fixed, routinely
processed, and embedded in paraffin. From paraffin blocks
2 lm sections were prepared and stained with the hematox-
ylin-eosin method. For IHC, a primary monoclonal mouse Ab,
anti-HNEJ-2 (Abcam), was used. IHC was performed using a
standard protocol. Slides were dewaxed, rehydrated, and
incubated in a 3% peroxide solution to block endogenous
peroxidase activity. Antigen retrieval was carried out by water
bath cooking in citrate buffer (pH 6.0). The LabVision (Thermo
Fisher Scientific) detection system was used, and DAB served
as the chromogen. Slides were counterstained with Mayer’s
hematoxylin. The intensity of the IHC reaction was evaluated
using a light microscope (Nikon eclipse 50i).
Biochemical Methods
The blood was collected from the right ventricle. Plasma was
separated by centrifugation at 1000g at 4°C for 10 minutes
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and stored in 80°C until assayed. Total cholesterol, level of
high-density lipoproteins (HDLs) and low-density lipoproteins
(LDLs), as well as triglycerides (TGs) were assayed using
commercially available kits (Roche Molecular Biochemical,
Pleasanton, CA). In addition, levels of some inflammation
markers, such as interleukin 6 (IL)-6), IL-12, vascular cell
adhesion protein 1 (VCAM-1), and monocyte chemoattractant
protein 1 (MCP-1), were measured by ELISA using commer-
cially available kits (R&D Systems, Minneapolis, MN). Aspar-
tate aminotransferase (AST) and alanine aminotransferase
(ALT) plasma levels were assayed using commercially avail-
able kits: Reflotron GPT, Reflotron GOT (Roche, Mannheim,
Germany), and Reflovet Plus equipment (Roche, Germany).
Apart from that, the level of TGs in the liver was measured
using Triglyceride Colorimetric Assay Kit (Cayman Chemical,
Ann Arbor, MI), according to the manufacturer’s instructions.
RT2 Profiler PCR Array
Total RNA was isolated from liver of 3 mice from the Alda-1
group and 3 mice from the control group using QIAzol Lysis
Reagent (QIAGEN), according to manufacturer’s instructions.
RNA concentration of each sample was measured at a
wavelength of 260 nm (A260) in an EPOCH Microplate
Spectrophotometer (BioTek Instruments). Purity of extracted
total RNA was determined by the A260/A280 ratio. All
samples had A260/A280 ratios of 1.9 to 2.1. Integrity of RNA
samples was confirmed by denaturing agarose gel electro-
phoresis. One thousand nanograms of total RNA were used as
a template to synthesize cDNA with the RT2 First Strand Kit
(SABiosciences, Frederick, MD). The RT2 Profiler PCR Arrays
(PAMM-157Z; SABiosciences) were used to analyze the
expression levels of 84 key genes involved in fatty liver
disease. The cDNA sample and 29SABiosciences RT2 qPCR
MasterMix were added to the PCR array plates, and PCR
reactions were performed using the 7900HT Fast Real-Time
PCR System (Applied Biosystems). Data were normalized to
the values for the housekeeping genes panel using a DDCt
method and analyzed by online RT2 Profiler PCR Array Data
Analysis Software (http://www.pcrdataanalysis.sabioscienc-
es.com/pcr/arrayanalysis.php).
Subcellular Fractionation
Isolation of mitochondria was performed at 4°C from freshly
harvested mouse liver. Two animals were pooled for samples
to obtain sufficient material for proteomic analysis. Homog-
enization was carried out in 250 mmol/L of sucrose and
1 mmol/L of EGTA (pH 7.8) with the addition of PMSF
(1 mmol/L) and a mix of protease inhibitors (approximately
100 lL for 3 g of tissue; Sigma-Aldrich). Nuclei and unbroken
cells were pulled down by centrifugation at 1000g for
10 minutes. Then, the mitochondrial fraction was obtained
by centrifugation of the supernatant at 12 000g for 10 min-
utes. The mitochondrial pellet was then purified by 3 cycles of
resuspension, homogenization, and centrifugation (at
12 000g for 15, 20, and 15 minutes). The cytosolic fraction
was obtained by further centrifugation of the supernatant
(90 minutes at 125 000g, 4°C). Samples were collected and
stored at 80°C until assayed.
Two-Dimensional Electrophoresis and Gel Image
Analysis
Mitochondrial pellets were resuspended in 1 mL of lysis
buffer containing 9.5 mol/L of urea, 4% CHAPS, 2% dith-
iothreitol (DTT), 0.5% Bio-Lyte 3-10 (Bio-Rad, Hercules, CA),
and a mix of protease inhibitors (100 lL for 3 mg of sample).
Samples were vortexed and left at 25°C for 30 minutes to
ensure maximal protein solubilization, then centrifuged at
12 000g for 15 minutes. The supernatant was harvested, and
the protein concentration was determined with the Bradford
method.19 The supernatant was then divided into aliquots
containing the appropriate amount of protein for single IPG
strips (200 lg for analytical gels) and stored at 80°C.
Before loading, samples were purified by precipitation with
two-dimensional (2D) electrophoresis (2DE) Clean-up kit (GE
Healthcare, Wilmington, MA) and resuspension in 300 lL of
rehydration buffer (8 mol/L of urea, 0.5% CHAPS, 0.2% DTT,
and 0.2% Bio-Lyte 3-10). Then, samples were loaded on linear
3-10 immobilized pH gradient 17-cm strips (Bio-Rad) using an
in-gel rehydration method and were rehydrated overnight in a
reswelling tray. Strips were focused with a multistep voltage
gradient from 400 to 3500 V (max 50 mA/IPG strip, 20°C)
for a total of 66 kVh. Once isoelectric focusing was
completed, the strips were equilibrated in buffer (6 mol/L
urea, 30% glycerol, 2% SDS, and 0.01% bromophenol blue)
with the addition of 1% w/v DTT (20 minutes) and 4.8% (w/v)
iodoacetamide (20 minutes), to ensure sufficient reduction
and alkylation of proteins. Second dimension (SDS-PAGE) was
performed using 12% T (total acrylamide concentration), 2.6%
C (degree of cross-linking) polyacrylamide gels without a
stacking gel, using the Protean II xi system (Bio-Rad). After
electrophoresis, gels were fixed overnight in ethanol/acetic
acid/water solution (4:1:5 v/v/v). Finally, protein profiles
were visualized by silver staining, using the Plus One silver
staining kit (GE Healthcare) with modifications to provide
compatibility with subsequent mass spectrometry (MS)
analysis.20 For analysis, silver-stained gels images were taken
using a Gel Doc XR scanner (Bio-Rad). PDQuest 8.0.1 (Bio-
Rad) was used for gel image analysis, quantification, and
statistical validation. In total, n=3 animals representing each
group with n=2 replicates for each animal (n=6 gel images per
group) were analyzed. All results were carefully verified
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manually, including verification of housekeeping proteins
chosen for normalization (local regression model) to ensure
accurate quantification. Student t-test with the level of
significance set at P<0.05 was used to reveal statistically
significant differences in protein expression. Significant
differences were further analyzed with a liquid chromatogra-
phy tandem MS (LC MS/MS) system to identify proteins of
interest.
LC MS/MS
Gel pieces containing protein spots of interest were
destained, reduced, alkylated, and digested with modified
trypsin (Sigma-Aldrich), according to the protocol described
by Shevchenko et al.21 Peptide mixtures were lyophilized and
stored at 80°C for further LC/MS analysis. Each sample
was resuspended in 0.1% trifluoroacetic acid and injected in
an Acclaim PepMap100 RP C18 75 lm i.d. 9 25 cm column
(LC Packings/Dionex, Sunnyvale, CA) by trap column (Pep-
Map100 RP C18 300 lm i.d. 9 5 mm column; LC Packings/
Dionex; Dionex). Peptides were separated in an acetonitrile
gradient (buffer A, 5% acetonitrile and 0.1% formic acid; buffer
B, 95% acetonitrile and 0.1% formic acid) with a flow rate of
300 nL/min with a Switchos/UltiMate 3000 RSLC nano
HPLC system (LC Packings/Dionex) and applied online to an
LCQ (Thermo Finnigan, San Jose, CA) ion-trap mass spec-
trometer. The mobile-phase gradient was started with an
increase from 0% to 25% B within 35 minutes, then increasing
to 40% B in 40 minutes, next rapidly increasing to 80% B
within 12 seconds, followed by 80% B isocratic for 5 minutes.
Finally, B phase was rapidly decreased to 0% and left isocratic
100% A for column equilibration for 30 minutes. The main
working liquid-junction electrospray ionization ion source
parameters were as follows: ion spray voltage, 1.5 kV;
capillary voltage, 10 V; and capillary temperature, 200°C.
Spectra were collected in full scan mode (270 to 1600 Da),
followed by 3 MS/MS scans of the 3 most intense ions from
full scan using dynamic exclusion criteria. Collected data were
analyzed by X!Tandem search algorithm (The Global Proteome
Machine Organization) and statistically validated with Trans-
Proteomic Pipeline software (Institute for Systems Biology,
Seattle, WA). Search parameters were set as follows:
taxonomy: mouse (SwissProt), enzyme: trypsin, missed
cleavage sites allowed: 3, fixed modification: carbamidometh-
yl, variable modifications: oxidation of methionine, peptide
fragment mass tolerance: 0.4 Da and selected device and
parent dm: ion trap (4 Da).
Immunoblotting
The purity of the fractions was assessed by immunoblotting
of cytochrome c oxidase (COX-IV) and a-tubulin. Isolated
mitochondria were lysed in PBS containing 1% Triton X-100,
0.1% SDS, 1 mmol/L of phenylmethylsulfonyl fluoride
(PMSF), 100 lmol/L of leupeptin, and 50 lmol/L of
pepstatin A. Samples, containing equal amounts of total
protein (as estimated with the Bradford method), were
mixed with gel loading buffer (50 mmol/L of Tris, 10% SDS,
10% glycerol, 10% 2-mercaptoethanol, and 2 mg/mL of
bromophenol blue) in a 4:1 ratio (v/v) and incubated at
95°C for 5 minutes. Samples (50 lg of protein) were
separated on SDS-PAGEs (7.5% to 15%, Mini Protean II;
Bio-Rad) using the Laemmli buffer system, and proteins were
semidry transferred to nitrocellulose membranes (Amersham
Biosciences). Membranes were blocked overnight at 4°C
with 5% (w/v) nonfat dried milk in TTBS and incubated
3 hours at room temperature with specific primary Abs:
1:5000 ANTI-COX-IV, 1:250 ANTI-a-tubulin (Sigma-Aldrich),
1:1000 ANTI-ECHS1 (Sigma-Aldrich), and 1:1000 ANTI-
ACAA2 (Sigma-Aldrich), then for 1 hour with HRP-conjugated
secondary Abs (Amersham Biosciences). Bands were devel-
oped with the use of ECL-system reagents (Amersham
Biosciences). Rainbow markers (Amersham Biosciences)
were used for molecular-weight determinations. Protein
pattern images were taken using ImageQuant Las 500 (GE
Healthcare, Chalfont, UK).
Hep2G Cell Culture
Human HepG2 cells were grown in a humidified incubator
containing 5% CO2 and 95% air at 37°C. They were grown
in DMEM medium (Sigma-Aldrich), supplemented with 5%
FBS (Gibco BRL, Gaithersburg, MD) and streptomycin
(100 lg/mL), penicillin (100 U/mL), and fungizone
(0.25 lg/mL). Cells were placed in 6-well plates (106 cells
per well) in 2 mL of culture medium and treated with
palmitic acid (50 lmol/L) and Alda-1 (10 lmol/L) versus
vehicle (0.1% DMSO) for 24 hours. Then, cells were lysed in
lysis buffer (1% Triton X-100, 0.1% SDS in PBS containing
1 mmol/L of PMSF, 100 lmol/L of leupeptin, and
50 lmol/L of pepstatin A). Protein concentrations of
lysates were determined using the Bradford method, and
immunoblotting with ANTI-ACAA2 (Sigma-Aldrich) and ANTI-
b-actin (Sigma-Aldrich) Abs was performed as described
above.
Statistical Analysis
Results are presented as a mean+SEM. Equality of variance
and normality of the data were checked, and then the
nonparametric Mann-Whitney’s U test (“en face” and “cross-
section” methods) or t test (other methods) were used for
statistical analysis of the data. P<0.05 was considered as
statistically significant.
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Results
Effects of Alda-1 on Atherosclerosis
Treatment with Alda-1 resulted in decrease of atherosclerotic
lesions in aortas of apoE/ mice, as evidenced by the en
face (8.51.2% vs. 16.72.2%; P<0.05; Figure 1A) and cross
section methods (65 2496943 lm2 vs. 87 817
7213 lm2; P<0.05; Figure 1B).
Alda-1 treatment did not significantly changed macro-
phage content in atherosclerotic lesions, as evidenced by
CD68 staining (292.4% vs. 35.82.5%; P=0.07; Figure 2)
and content of a-SMA staining in the fibromuscular cap
(2.80.6% vs. 3.60.9%; P=0.46; Figure 2). Alda-1 tended
to weaken 4-HNE protein adducts and nitrotyrosine staining
in atherosclerotic lesions from aortas of apoE/ mice;
however, such actions were not statistically significant
(Figure 2).
Treatment with Alda-1 did not change the expression of
genes connected with oxidative stress (catalase, superoxide
dismutase 2, and glutathione peroxidase 1), apoptosis (Bax
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Figure 1. A, Sudan IV–stained representative aortas in control group and Alda-1-treated group.
Percentage of area occupied by atherosclerotic lesions measured by the en face method in the control
group and Alda-1-treated group (P<0.05; n=10 per group). B, Representative micrographs showing Oil Red
O–stained lesions in control group and Alda-1-treated group. Atherosclerotic lesions area is measured by
the cross-section method in control group and Alda-1-treated group (P<0.05; n=10 per group). Alda-1
indicates N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide.
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and Bcl-2), and autophagy (Atg5, Beclin1, LC3A, and LC3B)
processes and mitochondrial function (PGC1a and Sirt1) in
aortas from apoE/ mice (Figure 3).
The levels of total cholesterol, HDLs, LDLs, TGs, VCAM-1,
MCP-1, IL-12, and IL-6 in blood did not change significantly
upon Alda-1 treatment in apoE/ mice (Table 1).
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Figure 2. The immunohistochemical staining of aortic roots from control (A) and Alda-1-treated (B) apoE
knockout mice. The figure shows immunohistochemical visualization of (A and B) CD68-positive
macrophages, SMA-positive smooth muscle cells, 4-HNE-protein adducts, and nitrotyrosine staining and
quantitative analysis of (C) CD68-positive macrophages (top panel) and SMA-positive smooth muscle
cells (lower panels). Magnification, 940. MeanSEM; P>0.05; n=10 per group. Alda-1 indicates N-(1,3-
benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide; apoE, apolipoprotein E; 4-HNE, 4-hydroxy-2-nonenal;
a-SMA, alpha-smooth muscle actin.
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Figure 3. Relative expression of genes connected with oxidative stress, apoptosis (A), and autophagy processes (B) in aortas from Alda-1-
treated apoE/ mice, in comparison to control. MeanSEM; P>0.05; n=5 per group. Alda-1 indicates N-(1,3-benzodioxol-5-ylmethyl)-2,6-
dichlorobenzamide; apoE, apolipoprotein E;
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Effects of Alda-1 on Liver Steatosis and 4-HNE
Staining
H&E staining did not reveal major disturbances of liver
structure in both untreated and Alda-1-treated mice. Portal
spaces were not enlarged, with only minimal lymphocytic
infiltrates in part of them. In both groups, signs of hepatocyte
damage were visible: In livers of untreated mice, cytoplasm
was granular with small and sometimes bigger, clear droplets
present in 80% to 90% of hepatocytes (Figure 4A). The picture
was consistent with severe microvesicular steatosis. More-
over, some hepatocytes had enlarged, hyperchromatic nuclei
and single cells were binucleated. In livers of Alda-1-treated
mice, similar, but less pronounced, cytoplasmic changes in
hepatocytes were visible: Small lipid droplets were present
in approximately 30% to 40% of hepatocytes (especially in
centrilobular locations; Figure 4B). Bigger lipid droplets were
not visible. Cells with enlarged, hyperchromatic nuclei and
binucleated cells were still detectable. Moreover, treatment
with Alda-1 resulted in a significant decrease of TG level in
liver of apoE/ mice (Figure 4). Plasma AST and ALT levels
also did not differ between C57BL/6J (wild-type), apoE/,
and Alda-1-treated apoE/ mice (Figure 5).
4-HNE staining of livers revealed a decrease of 4-HNE
signal in Alda-1-treated apoE/ mice, as compared to
untreated mice (Figure 4C and 4D).
RT2 Profiler PCR Array
Use of Mouse Fatty Liver RT² Profiler PCR Array revealed that
Alda-1 treatment was associated with significant changes of
expression of 3 genes; 1 (glucose-6-phosphate dehydrogenase
Table 1. Plasma Level of Total Cholesterol, High-Density Lipoproteins (HDL), Low-Density Lipoproteins (LDL), Triglycerides (TG),
Vascular Cell Adhesion Protein 1 (VCAM-1), Monocyte Chemoattractant Protein 1 (MCP-1), Interleukin-12 (IL-12), and Interleukin-6
(IL-6) in a Control and Alda-1-Treated Group
Total Cholesterol (mmol/L) HDL (mmol/L) LDL (mmol/L) TG (mmol/L) VCAM-1 (ng/mL) MCP-1 (pg/mL) IL-12 (pg/mL) IL-6 (pg/mL)
Control 13.380.59 3.730.76 8.250.85 1.360.22 9.230.33 73.347.42 11.440.86 9.873.95
Alda-1 10.802.87 2.750.21 8.602.22 1.600.21 9.190.12 76.207.07 8.760.92 6.970.83
Data presented as a meanSEM; P>0.05, n=10 per group.
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Figure 4. Representative images of livers of 6-month-old apoE/ mice (A and C) and Alda-1-treated apoE/ mice (B and D). The figure
shows hematoxylin and eosin staining (A and B), immunohistochemical visualization of 4-HNE protein adducts (C and D), and quantitative
analysis of the triglyceride content in the liver (right panel). Magnification, 940. MeanSEM; P<0.05; n=5 per group. Alda-1 indicates N-(1,3-
benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide; apoE, apolipoprotein E; 4-HNE, 4-hydroxy-2-nonenal.
DOI: 10.1161/JAHA.114.001329 Journal of the American Heart Association 8
ALDH2 Activation Inhibits Atherosclerosis Stachowicz et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on A
pril 10, 2020
X-linked) was up-regulated and 2 (acyl-coenzyme A [CoA]
oxidase 1 and insulin-like growth factor binding protein 1)
were down-regulated (Table 2; Figure 6).
Influence of Alda-1 on Liver Mitoproteome
The representative 2DE gel image of liver mitochondrial
proteins of apoE/, as well as selected pairs of spots
showing differences between apoE/ and Alda-1-treated
apoE/ mice, are presented in Figure 7A and 7B, respec-
tively. LC-MS/MS analysis from numbered spots showing
significant differences are listed in Table 3. Quantitative
results of differences in expression of mitochondrial proteins
are shown in Figure 8. Accuracy of the isolation protocol and
purity of the mitochondrial fractions were assessed by
immunoblotting for a-tubulin and COX-IV (Figure 7C). Fur-
thermore, the Alda-1-related increase in enoyl-CoA hydratase
(ECHS1) and 3-ketoacyl-CoA thiolase (ACAA2) levels in
mitochondria were confirmed by Western blotting (Figure 9A).
COX-IV was used as a mitochondrial loading control.
Interestingly, Alda-1 slightly up-regulated COX-IV expression
in liver mitochondria of apoE/ mice (Figure 9A).
Alda-1 Treatment of Hep2G Cells
Alda-1 administration (10 lmol/L) resulted in the increase of
ACAA2 level in human Hep2G cells treated with palmitic acid
(50 lmol/L), as assessed by Western blotting (Figure 9B).
Discussion
It is known that ROS-dependent peroxidation of polyunsatu-
rated fatty acids, associated with generation of toxic
aldehydes, is related to dysfunction of mitochondria and
plays a role in atherogenesis and steatosis of the liver.22,23 In
the present study, we observed that use of Alda-1—an
activator of ALDH2, which is the main mitochondrial enzyme
responsible for detoxification of aldehydes—is associated
with inhibition of atherogenesis and attenuation of hepatic
steatosis in apoE/ mice. To the best of our knowledge, this
is the first report about the direct antiatherosclerotic activity
of ALDH2 and possibility of use of its small-molecular-weight
activator to inhibit atherogenesis in vivo. The relationship
between ALDH2 and atherosclerosis has been only suggested
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Figure 5. The aspartate aminotransferase (AST) (A) and the alanine aminotransferase (ALT) (B) plasma levels in C57BL/6J (wild-type) mice,
apoE / mice, and Alda-1-treated apoE / mice. MeanSEM; P>0.05; n=8 per group. Alda-1 indicates N-(1,3-benzodioxol-5-ylmethyl)-2,
6-dichlorobenzamide; ALT, alanine aminotransferase; apoE, apolipoprotein E; AST, aspartate aminotransferase.
Table 2. Genes Involved in Fatty Liver Disease and Expressed Differently Between Alda-1 Group and Control Group
Gene Name Description Fold Change P Value (t test)
G6pdx Glucose-6-phosphate dehydrogenase X-linked 2.03 0.008217
Acox1 Acyl-coenzyme A oxidase 1, palmitoyl –2.20 0.007957
Igfbp1 Insulin-like growth factor-binding protein 1 –2.94 0.004703
Fold change >2.0; P<0.05; n=3 per group.
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in a few reports pertaining to the associations of certain ALDH2
polymorphisms and plasma HDL-C levels as well as incidence/
severity of coronary heart disease in humans.24,25 In our hands,
however, the decrease of atherosclerotic lesions caused by
Alda-1 was not associated with any significant changes in
plasma lipid profile. The action of Alda-1 in apoE/ mice was
not associated with its influence on inflammatory processes
related to progression of atherogenesis, because Alda-1
neither changed the macrophage content in the plaques nor
influenced levels of atherosclerosis-related plasma markers of
inflammation (slight decrease in levels of proinflammatory
cytokines, such as IL-12 and IL-6, did not reach statistical
significance).
Recently, the beneficial influence of ALDH2 stimulation in
acute ischemia-reperfusion injury of heart or brain has been
attributed to many possible mechanisms, including attenua-
tion of oxidative stress and clearance of reactive aldehydes,26
improvement of mitochondrial function and decrease of
apoptosis,27 and augmentation28 or inhibition of autophagy.29
In our setting, Alda-1 tended to decrease the content of 4-
HNE protein adducts and nitrotyrosine in atherosclerotic
plaques, but such action did not reached statistical signifi-
cance. Moreover, there were no changes upon Alda-1
treatment in aortic mRNA levels of selected factors involved
in antioxidative defense (SOD2, CAT, GPX1), regulation of
apoptosis (Bax and Bcl-2), mitogenesis (PGC1a and Sirt1), and
autophagy (Atg5, Beclin1, LC3A, and LC3B). Thus, the
question about exact molecular mechanism of antiatheroscle-
rotic action of Alda-1 in apoE/ mice remains open. Our
study does not allow for determining the cellular target of
antiatherosclerotic action of Alda-1. Previous reports clearly
show the presence and biological function of ALDH2 in
smooth muscle cells and endothelium. Interestingly, recently,
Solito et al. have shown that Alda-1-dependent activation of
ALDH2 prevents endothelial cell dysfunction induced by b-
amyloid in vitro.16 Whether endothelial action of Alda-1 could
be responsible for its antiatherosclerotic effect requires
further investigation.
Growing number of evidence point to important mutual
relationships between hepatic steatosis and atherosclerosis:
NAFLD may serve as a predictor of CVD, and atherosclerosis
seems to be a major player in the natural course of
NAFLD.30,31 Importantly, mitochondrial dysfunction repre-
sents an important possible mechanism linking NAFLD and
atherosclerosis.5,6 In our hands, stimulation of mitochondrial
ALDH2 by Alda-1 attenuated hepatic steatosis in apoE/
mice and decreased tissue TG content, which was accompa-
nied by lower 4-HNE protein adduct formation. To understand
the mechanism of Alda-1 action in liver of apoE/ mice, we
first screened the influence of Alda-1 on expression of a set of
genes typically linked to fatty liver disease; Alda-1 exerted
only a small effect: Levels of only 3 of 84 genes were
modestly changed. Liver expression of mRNA of insulin-like
growth factor binding protein 1 (IGFBP-1) was down-regulated
upon treatment, which, at first glance, seems to be contra-
dictory to results of Li et al., who described that elevated
IGFBP-1 liver and serum levels to be candidates for markers of
early liver steatosis.32 However, although these investigators
used mouse model, they fed animals with alcohol and studied
an early stage of alcohol induced liver injury, not NAFLD.
Interestingly, a recent study of Kwon et al. shows that
deficiency of ALDH2 worsens liver inflammation and fibrosis
in mice, but makes the hepatocytes more resistant to
steatosis.33 Importantly, these results, somehow contradic-
tory to ours, were again relevant to alcoholic fatty liver
disease.
Mitochondria are at the crossroads of many cellular
processes related to supply of energy, metabolism of lipids
and amino acids, signaling, regulation of cell death, and cell
growth. It was demonstrated that mitochondrial dysfunction
plays an important role in fatty liver disease.6,7,34 Over the
last decade, the proteomic approach has been increasingly
used to describe the role that mitochondria play in various
disorders.35 The proteomic analysis of atherosclerotic plaques
in apoE/ mice, first done by Mayr et al., still represents a
methodological challenge36; therefore, in this study, we
Figure 6. Volcano plot graphs of mouse fatty liver PCR array.
Graph shows the log2 of fold change of gene expression between
the Alda-1 group and control group versus P value from the t test.
up-regulation, down-regulation. Blue line indicates threshold
0.05 for P value. Acox indicates acyl-CoA oxidase 1; Alda-1, N-(1,3-
benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide; G6pc, glucose-6-
phosphate, catalytic; G6pdx, glucose-6-phosphate dehydrogenase
X-linked; Igfbp1, insulin-like growth factor binding protein 1.
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focused on liver mitochondria. The analysis of liver mitopro-
teome-treated apoE/ mice revealed 20 differentially
expressed proteins upon Alda-1 treatment. Among them,
the most up-regulated were proteins related to beta-oxidation
of fatty acids in mitochondria including enoyl-CoA hydratase
(ECHS1), ACAA2, 3-hydroxyacyl-CoA thiolase (HCDH), and
medium-chain acyl-CoA dehydrogenase (MCAD). All these
proteins take part in fatty acid oxidation (FAO) of medium- and
short-chain-length fatty acids.37 Interestingly, COX-IV levels in
mitochondrial fractions tended to follow the pattern of ACAA2
and ECHS1, which may indicate a positive influence of Alda-1
on mitogenesis in the liver. Of note, the influence of Alda-1 on
expression of ACAA2 is preserved in a crude in vitro model of
lipotoxicity—Hep2G cells cultured in the presence of palmitic
acid.
Surprisingly, Alda-1 administration down-regulated expres-
sion of peroxisomal acyl-CoA oxidase 1 (ACOX1), both at the
gene and protein level. It should be noted, however, that
ACOX1 is involved in the first step of peroxisomal FAO of very
long fatty acids, which is not coupled to ATP synthesis and
yields toxic hydrogen peroxide.38 It is recognized that
impairment of liver FAO is a hallmark of NAFLD. Zhang et al.
have shown that down-regulation of ECHS1 is associated with
hepatic steatosis in rats after exposure to a high-fat diet.39
ECHS1/HCDH/ACAA2 constitute heterotrimeric MTP protein
that mediates the last 3 steps of FAO for long-chain-length
fatty acids.40 It was shown that mice heterozygous for the
MTP defect (MTP+/) develop hepatic steatosis and insulin
resistance.41 Clearly, up-regulation by Alda-1 of proteins
involved in mitochondrial FAO could represent the mechanism
of its beneficial action in hepatic steatosis.
In our hands, treatment with Alda-1 resulted in a significant
increase in mitochondrial expression of histidine triad nucleo-
tide-binding protein 2 (HINT2). Interestingly, Martin et al. have
shown that Hint2 knockout (KO) mice have decreased cellular
respiration, display deformed mitochondria, and develop fatty
liver.42 Of note, Hint2 KO mice show a global increase in
mitochondrial protein acetylation, which could reduce the
activity of proteins involved in FAO. Given that HINT2 positively
regulates mitochondrial lipid metabolism, respiration, and
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Figure 7. Representative 2D map of mitochondrial proteins expressed in 6-month-old apolipoprotein E–deficient mice (A), with magnifications
of spot pairs corresponding to enoyl-CoA hydratase (ECHS1), 3-ketoacyl-CoA thiolase (ACAA2), and glutathione peroxidase 1 (GPX1) (B). Purity
of mitochondrial fraction was assessed by the Western blotting method, showing the absence of cytosolic a-tubulin l in mitochondrial fraction
(C). Alda-1 indicates N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide; apoE, apolipoprotein E; COX-IV, cytochrome c oxidase.
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glucose homeostasis, it is tempting to speculate that up-
regulation of HINT2 by Alda-1 may be responsible for reduction
of hepatic steatosis in apoE/ mice.
Mitochondrial oxidative stress plays a pivotal role in the
development of NAFLD.43 The mitochondrial abnormalities
associated with NAFLD include ultrastructural lesions, deple-
tion of mtDNA, decreased activity of respiratory chain
complexes, and impaired mitochondrial b-oxidation.7 Mito-
chondrial respiratory chain dysfunction can directly lead to the
production of ROS. Moreover, cytochrome c oxidase can be
inhibited by low levels of ROS and 4-HNE.7 Importantly, Alda-1
changed the expression of proteins related to oxidative stress
in liver mitochondria of apoE/ mice; it up-regulated
glutathione peroxidase-1 (GPX1), as well as down-regulated
uricase (UOX), at protein levels and up-regulated glucose-6-
phosphate dehydrogenase X-linked (G6PDX) mRNA. GPX1 is
a crucial antioxidant enzyme presented in cytosol and
mitochondria and involved in preventing the harmful accumu-
lation of intracellular hydrogen peroxides and lipid peroxides
by converting them to water and alcohols, respectively.44 In
our previous study, we have shown that GPX1 is down-
regulated in liver mitochondria of apoE/ mice, compared to
C57BL/6J mice.45 Furthermore, it was demonstrated that
deficiency of GPX1 accelerates the progression of atheroscle-
rosis in apoE/ mice.46,47 Of note, G6PDX, up-regulated by
Alda-1 at the gene level, catalyzes the rate-determining step in
the pentose phosphate pathway and produces the NADPH
necessary to fuel glutathione recycling for use by GPX to
remove excess hydrogen peroxides.48 In turn, uric acid is a
powerful antioxidant and down-regulation of UOX, which
catalyzes the oxidation of uric acid to 5-hydroxyisourate,
may result in maintaining its high levels in mitochondria. On
the other hand, Alda-1 treatment was associated with down-
regulation of superoxide dismutase [Cu-Zn] (SOD1), an anti-
oxidant enzyme localized mainly in the cytosol with a smaller
fraction in the intermembrane space (IMS) of mitochondria.49
Table 3. Differentially Expressed Proteins in Liver Mitochondria of Alda-1-Treated ApoE/ Mice*
No. Protein
UniProtKB
Accession No.
Molecular
Mass (kDa) pI
Unique
Peptides
Total
Peptides
Protein
Coverage (%) Tandem Score
1 Tropomyosin 1, alpha Q8BP43 32.8 4.69 6 16 15.8 48.4
2 Cytochrome b5 P56395 15.2 4.96 3 14 41.0 53.5
3 Cathepsin Z Q9WUU7 34 6.13 5 20 16.3 41.6
4 Superoxide dismutase [Cu-Zn] P08228 15.9 6.02 4 14 32.5 39.1
5 Component of pyruvate dehydrogenase complex,
mitochondrial
Q8BMF4 67.9 8.81 8 24 16.0 37.2
6 Glutathione peroxidase 1 P11352 22.3 6.73 3 9 14.9 51.0
7 Isovaleryl coenzyme A dehydrogenase Q9JHI5 46.3 8.53 8 38 19.8 67.5
8 Hydroxymethylglutaryl-CoA lyase, mitochondrial P38060 34.1 8.55 4 14 16.0 43.1
9 Acyl-coenzyme A oxidase 1 Q9R0H0 74.6 8.64 3 7 5.6 25.0
10 Fumarylacetoacetate hydrolase domain-containing
protein 2A
Q3TC72 34.7 8.42 3 8 8.9 20.1
11 Probable 4-hydroxy-2-oxoglutarate aldolase,
mitochondrial
Q9DCU9 34.6 7.61 6 21 21.5 17.4
12 Isocitrate dehydrogenase NADP, cytoplasmic O88844 47.4 6.48 3 6 9.5 20.6
13 Uricase P25688 35 8.48 6 16 23.0 35.0
14 Medium-chain–specific acyl-CoA dehydrogenase,
mitochondrial
P45952 46.5 8.6 13 46 25.0 109.5
15 Histidine triad nucleotide-binding protein 2 Q9D0S9 17.3 9.83 5 15 30.1 25.5
16 Hydroxyacyl-coenzyme A dehydrogenase,
mitochondrial
Q61425 34.4 8.76 4 12 9.9 8.9
17 3-Ketoacyl-CoA thiolase, mitochondrial Q8BWT1 41.8 8.33 11 42 38.0 122.6
18 Uricase P25688 35 8.48 28 98 48.2 233.9
19 Enoyl-CoA hydratase, mitochondrial Q8BH95 31.5 8.76 9 32 34.5 69.6
20 ATP synthase subunit alpha Q03265 54.6 9.22 4 9 9.9 18.1
pI indicates isoelectric point. Tandem score is the log10 of expectation value, which reflects the number of matches expected to be found by chance in a database.*P<0.05; n=3 per group.
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Figure 9. Western blotting of ECHS1, ACAA2, and COX-IV in liver’s mitochondria of 6-month-old apoE/ mice and Alda-1-treated apoE/
mice (A). Expression of ACAA2 in the human hepatocyte cell culture (HepG2) treated with palmitic acid (50 lmol/L) and Alda-1 (10 lmol/L)
versus palmitic acid (50 lmol/L) alone (control) (B). MeanSEM; P<0.05; n=3 per group. ACAA2 indicates 3-ketoacyl-CoA thiolase; Alda-1, N-
(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide; apoE, apolipoprotein E; COX-IV, cytochrome c oxidase; ECHS1, enoyl-CoA hydratase; GPX1,
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The trafficking of SOD1 to mitochondria seems to be required
in protecting cells against mitochondria-derived oxidative
stress. However, it was shown that SOD1 competes with
cytochrome c for superoxide in IMS and generates hydroper-
oxide, which then could react with cytochrome c and form a
strong oxidant—peroxidase compound I-type intermediate,
leading to mitochondrial injury and apoptosis.50 Interestingly,
one of the mitochondrial FAO proteins up-regulated by Alda-1,
ACAA2, was found to colocalize with BCL2/adenovirus E1B
19 kDa-interacting protein 3 (BNIP3) in mitochondria and to
abolish BNIP3-mediated apoptosis in vitro.51 Clearly, further
investigation is required to clarify the effect of Alda-1 on
proteins related to mitochondrial oxidative stress and regula-
tion of apoptosis.
It was shown that the association between regular alcohol
intake and incident carotid atherosclerosis (early atherogen-
esis) is J-shaped, with light drinkers facing a lower risk than
either heavy drinkers or abstainers.52 Interestingly, the exact
molecular mechanism of such a phenomenon is still not clear.
It has been demonstrated that mitochondrial ALDH2 is a key
enzyme downstream of ethanol-induced protection in the
heart ischemia model.15 Given that stimulation of ALDH2
activity by Alda-1 mimics the induction of the enzyme by
regular intake of low amounts of ethanol, we are tempted to
speculate that ALDH2 induction may represent a plausible
explanation of the beneficial action of low amounts of ethanol.
In summary, we have shown that prolonged use of ALDH2
activator Alda-1 was associated with a decrease of athero-
sclerosis and attenuation of hepatic steatosis in apoE/
mice. The antiatherosclerotic action of Alda-1 in apoE/
mice was not associated with changes in plasma lipid profile.
The analysis of liver mitoproteome revealed multiple effects of
Alda-1 on mitochondrial proteins related to beta-oxidation and
oxidative stress defense. The pattern of changes suggests a
beneficial, mitochondrial effect of Alda-1 in NAFLD; however,
the exact liver functional consequences of the revealed
alterations as well as the mechanism(s) of anti-atherosclerotic
Alda-1 action require further investigation.
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